A5030689616- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer survivorship and care
- Breast Cancer Treatment Studies
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Cancer-related Molecular Pathways
- Chemotherapy-related skin toxicity
- Lung Cancer Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Nutrition and Health in Aging
- Childhood Cancer Survivors' Quality of Life
- Colorectal Cancer Treatments and Studies
- Bone health and treatments
- Neutropenia and Cancer Infections
- Dietary Effects on Health
- Chronic Lymphocytic Leukemia Research
- Chemotherapy-induced cardiotoxicity and mitigation
- Neuroendocrine Tumor Research Advances
- Health Systems, Economic Evaluations, Quality of Life
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Cancer-related cognitive impairment studies
- Peptidase Inhibition and Analysis
University of Alberta
2016-2025
Dhaka Medical College and Hospital
2025
Alberta Health Services
2020-2022
Cancer Institute (WIA)
2001-2021
Alberta Cancer Foundation
2004-2021
College of the Holy Cross
2006-2020
Technical University of Munich
2018
Klinikum rechts der Isar
2018
UCSF Helen Diller Family Comprehensive Cancer Center
2018
University of California, San Francisco
2018
In the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC) [hazard ratio (HR) 0.58; P < 0.001]. Herein, we report results overall and by subgroups extended follow-up. this double-blind, phase 3 study, post-menopausal ER+/HER2− ABC who had not received prior...
To determine the effects of preoperative exercise training on cardiorespiratory fitness in patients undergoing thoracic surgery for malignant lung lesions.Using a single-group design, 25 with suspected operable cancer were provided structured until surgical resection. Exercise consisted 5 endurance cycle ergometry sessions per week at intensities varying from 60% to 100% baseline peak oxygen consumption (VO(2 peak)). Participants underwent cardiopulmonary testing, 6-minute walk (6 MW), and...
An Institute of Medicine report recommends that patients with cancer receive a survivorship care plan (SCP). The trial objective was to determine if an SCP for breast survivors improves patient-reported outcomes.Women early-stage who completed primary treatment at least 3 months previously were eligible. Consenting allocated within two strata: less than 24 and ≥ since diagnosis. All transferred their own physician (PCP) follow-up. In addition discharge visit, the intervention group received...
We assessed the Aurora A kinase inhibitor, alisertib, plus paclitaxel (henceforth referred to as alisertib/paclitaxel) second-line treatment for SCLC.In this double-blind study, patients with relapsed or refractory SCLC were stratified by relapse type (sensitive versus resistant refractory) and brain metastases randomized 1:1 alisertib/paclitaxel placebo placebo/paclitaxel) in 28-day cycles. The primary end point was progression-free survival (PFS). Associations of c-Myc expression tumor...
Abstract Purpose: To evaluate the cardiovascular risk profile of a subset patients with early-stage breast cancer treated adjuvant taxane-anthracycline–containing chemotherapy and/or trastuzumab (Herceptin). Experimental Design: Twenty-six (mean, 20 months postchemotherapy) and 10 healthy age-matched women were studied. We measured 14 metabolic vascular established disease (CVD) factors, body mass index, cardiorespiratory fitness, left ventricular systolic function. All assessments done...
This multicenter, randomized, double-blind, phase II study assessed safety and efficacy of axitinib plus docetaxel in metastatic breast cancer (MBC).Women with MBC were randomly assigned 2:1 to receive 80 mg/m2 once every 3 weeks 5 mg twice per day (combination arm) or placebo (placebo arm), following a lead-in I trial. The primary end point was time progression (TTP).In all, 168 patients enrolled; 112 56 placebo. Median TTP numerically longer the combination arm than (8.1 v 7.1 months), but...
PALOMA-2 confirmed that first-line palbociclib + letrozole improved progression-free survival (hazard ratio, 0.58; 95% confidence interval, 0.46-0.72) in postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). This analysis evaluated palbociclib-associated hematologic adverse events (AEs) and provides insight on managing these AEs.Postmenopausal ER+/HER2- ABC were randomly assigned 2:1 to (2.5 mg daily...
Cancer care has expanded from a disease-focused, survival-oriented model to an approach that now considers how survivors can live well in the aftermath of intensive therapy, where they may deal with significant changes their bodies, mental health or emotional well-being. Research evidence supports benefit exercise during and following cancer treatments for cancer-related symptoms, physical functioning fitness, health-related quality life. To move this efficacy into practice, we designed...
BackgroundOptimal dosing of bone-targeted agents (BTAs), in patients with bone metastases remains an important clinical question. This trial compared 4-weekly versus 12-weekly therapy.Patients and methodsPatients from breast or castration-resistant prostate cancer (CRPC), who were going to start already on BTAs, randomised 1:1 BTA treatment for one year. Primary end point was change health-related quality life (HRQoL)-physical function European Organisation Research Treatment Cancer...
Abstract Background. Anemia in patients with solid tumors is a common problem that associated impaired exercise capacity, increased fatigue, and lower quality of life (QoL). Erythropoiesis-stimulating agents (ESAs) have been shown to improve these outcomes; however, it unknown if additional benefits can be achieved aerobic training. Methods. We conducted single-center, prospective, randomized, controlled trial 55 mild-to-moderately anemic tumors. Patients were randomized either darbepoetin...
MicroRNAs (miRNAs) post-transcriptionally regulate hundreds of gene targets involved in tumorigenesis thereby controlling vital biological processes, including cellular proliferation, differentiation and apoptosis. MiRNA profiling is an emerging tool for the potential early detection a variety malignancies. This study was conducyed to assess feasibility methodological robustness quantifying sputum miRNAs, employing quantitative real-time polymerase chain reaction (RT-qPCR) cluster analysis...